v3.26.1
Segment Information (Tables)
 6 Months Ended
Jun. 30, 2026
Segment Information [Abstract]  
Segment Information
The following table sets forth information on segment profit or loss, including significant segment expenses (in thousands):
 
 Three Months Ended Six Months Ended
 June 30, June 30,
  2026   2025   2026   2025 
Revenue$267,949  $452,049  $514,042  $583,660 
                
Less:               
Cost of sales 2,563   3,541   5,398   4,904 
Drug discovery 29,120   30,255   57,677   57,244 
Drug development 103,958   117,689   208,140   230,635 
Medical affairs 11,318   7,826   21,307   13,468 
Manufacturing and development chemistry 20,639   21,545   40,947   35,826 
R&D support 26,974   20,607   49,405   41,159 
Selling, general and administrative 130,075   81,081   262,012   148,061 
Other segment items (1) 57,948   45,954   76,330   75,750 
Consolidated net income (loss)$(114,646)  $123,551  $(207,174)  $(23,387) 
 
(1)  Other segment items include stock-based compensation expense, investment income, interest expense, gain or loss on investments, other income or expense and income tax expense or benefit.